- Home
- Incretin Management in Type 2 Diabetes
Incretin Management in Type 2 Diabetes
- MI/ACS
Available Credit:
- 1.00 EBAC
Course Published On:
Course Expiry Date:
Please Note
This content is not indented for UK HCPs
Overview
In this educational hub ‘Incretin Management in Type 2 Diabetes’ the faculty present the importance of screening and early intensification for better glycaemic control and improved vascular and mortality outcomes in type 2 diabetes.
In this series of CME accredited videos and downloadable summaries, leading global experts will guide you through how the incretin system works, what happens to it in type 2 diabetes and how to optimise the use of incretin-based agents for better patient outcomes.
Disclosure
In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.
The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
This programme is supported by an unrestricted educational grant by Novo Nordisk A/S. The scientific programme has not been influenced in any way by the sponsors.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session of ‘Incretin Management in Type 2 Diabetes’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Target Audience
This programme is intended to educate:
- Primary care physicians (PCPs)/ General Practitioners (GPs)
- Endocrinologists
- Diabetologists
- Nurses
Learning Objectives
The overall programme, ‘Incretin Management in Type 2 Diabetes’’, endeavours to best address the following learning objectives:
- Recall the components of the ‘ominous octet’ & how they contribute to T2DM development
- Identify underlying facets of clinical inertia in T2DM care
- Describe how early adoption of intensive glycaemic control leads to better outcomes in T2DM
- Recall efficacy & the mode of action of various incretin-based treatments
- Adopt an early, intensive glucose-lowering strategy in appropriate individuals
- Select appropriate incretin treatment & dosing regimens according to patient profiles
- Identify individuals likely to gain cardiovascular benefit from GLP-1RAs
- Select appropriate actions following adverse events from incretin-based treatments
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Session 1 | Diabetes pathophysiology and the 'ominous octet' | 10 minutes | Silvio Inzucchi |
| Session 2 | The incretin system & incretin-targeting agents | 10 minutes | Silvio Inzucchi |
| Session 3 | Therapeutic inertia in T2DM | 10 minutes | Kamlesh Khunti |
| Session 4 | Early glycaemic control in T2DM | 10 minutes | Kamlesh Khunti |
| Session 5 | The use of GLP-1 RAs in T2DM | 10 minutes | Sarah Davies |
| Session 6 | Incretin-based drugs: What does the data say? | 10 minutes | Sarah Davies |
| Session 7 | Incretin-based drugs: Mode of action/delivery & dosing schedule | 10 minutes | G Michael Felker |
| Session 8 | Appropriate prescribing practices | 10 minutes | G Michael Felker |
| Session 9 | Beyond glycaemic control: Cardiovascular benefits | 10 minutes | Steven B Feinstein |
| Session 10 | Beyond glycaemic control: Weight control | 10 minutes | Steven B Feinstein |
Incretin-based drugs: Mode of action/delivery & dosing schedule
Duration: 10 minutes
Speakers: G Michael Felker
Course Director
Speaker
Speaker
Speaker
Speaker
1.00 European Board for Accreditation in Cardiology (EBAC)
Related Courses
- 1.00 European Board for Accreditation in Cardiology (EBAC)
Published:
Learning objectives
- Discuss the current practice gaps in hypercholesterolaemia management
- Recall best practice for assessing CV risk, defining LDL-C targets and offering patient education
- Stratify patients by CV risk category
- Select cholesterol-lowering therapies according to risk category and LDL-C target
- 1.00 EBAC
Published:
Learning objectives
- Recall the supportive evidence underpinning recommended antiplatelet approaches in individuals with unknown coronary anatomy, including choice of therapy, duration, timing and loading doses
- Compare the design of different clinical trials that have influenced antiplatelet therapy choice in NSTE-ACS patients who proceed to PCI
- Apply trial data and clinical guidelines on the use of antiplatelet therapy in patients undergoing revascularisation to a surrogate patient case
- 1.00 EBAC
Published:
Learning objectives
- Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
- Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
- Assess the merits of adopting emerging technologies within their practice
- Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
- Interact with opinion leaders in their profession
- 1.00 EBAC
Published:
Learning objectives
- Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
- Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
- Assess the merits of adopting emerging technologies within their practice
- Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
- Interact with opinion leaders in their profession
- 1.00 EBAC
Published:
Learning objectives
- Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
- Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
- Assess the merits of adopting emerging technologies within their practice
- Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
- Interact with opinion leaders in their profession
- 1.00 EBAC
Published:
Learning objectives
- Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
- Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
- Assess the merits of adopting emerging technologies within their practice
- Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
- Interact with opinion leaders in their profession
- 1.00 EBAC
Published:
Learning objectives
- Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
- Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
- Assess the merits of adopting emerging technologies within their practice
- Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
- Interact with opinion leaders in their profession
- 1.00 EBAC
Published:
Learning objectives
- Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
- Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
- Assess the merits of adopting emerging technologies within their practice
- Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
- Interact with opinion leaders in their profession
- 1.00 EBAC
Published:
Learning objectives
- Evaluate emerging clinical data related to interventional cardiology practice including for both devices and pharmacology
- Recognise the latest interventional approaches for SHD and Complex PCI available for the optimal management of CV patients
- Assess the merits of adopting emerging technologies within their practice
- Apply the practical guidance to maximise success of their interventional procedures within TAVR, Mitral & Tricuspid Valve Replacement and Complex PCIs
- Interact with opinion leaders in their profession